Clinical Trials Browser

Phase 1 × Completed × veliparib × Clear all

Burkitt Lymphoma, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00576654 2025-04-15

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Completed

73 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02631733 2025-02-10

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Phase 1 Completed

18 enrolled

Other solid neoplasm

Malignant Solid Neoplasm

NCT01618357 2024-05-22

Pre-Operative Radiation and Veliparib for Breast Cancer

Phase 1 Completed

19 enrolled

Breast

Breast Neoplasms

NCT02723864 2022-02-08

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Phase 1 Completed

53 enrolled 20 charts

Tumor-Agnostic

Neoplasms

NCT01063816 2021-08-02

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Phase 1 Completed

79 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01123876 2021-08-02

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Phase 1 Completed

60 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01908478 2020-07-15

VelGemRad

Phase 1 Completed

34 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01749397 2020-07-02

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 1 Completed

29 enrolled

Gynecologic

Stage IV Fallopian Tube Cancer AJCC v6 and v7

NCT01445522 2019-12-17

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

Phase 1 Completed

35 enrolled

Lymphoid

Lymphoma, Neoplasms

NCT00994071 2019-12-09

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Phase 1 Completed

9 enrolled

CNS

Astrocytoma, Brain Neoplasms, Ependymoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT02944396 2019-10-23

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01459380 2019-07-22

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 1 Completed

41 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01281852 2019-07-18

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Phase 1 Completed

37 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Phase 1 Completed

98 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

NCT00770471 2018-06-27

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1 Completed

24 enrolled

CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT02210663 2018-05-07

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Phase 1 Completed

16 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT01145430 2017-12-22

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Phase 1 Completed

45 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00526617 2017-11-21

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Phase 1 Completed

41 enrolled

BreastDermatologicGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

NCT00649207 2017-11-21

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Phase 1 Completed

80 enrolled

CNS

Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Neoplasm Metastasis, Nervous System Neoplasms

NCT01085422 2017-11-21

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Phase 1 Completed

35 enrolled

Genitourinary

Prostatic Neoplasms

NCT01264432 2017-11-21

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

Phase 1 Completed

34 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01853306 2017-11-21

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Phase 1 Completed

71 enrolled

Tumor-Agnostic

Neoplasms

NCT01589419 2017-11-20

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

Phase 1 Completed

32 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT01617928 2017-11-20

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

Phase 1 Completed

12 enrolled

Other solid neoplasm

Solid Tumors

NCT02009631 2017-11-20

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Phase 1 Completed

45 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT02483104 2017-11-20

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Phase 1 Completed

9 enrolled

Gynecologic

Ovarian Neoplasms

NCT01104259 2017-08-10

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Phase 1 Completed

50 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00553189 2017-07-02

Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

Phase 1 Completed

31 enrolled

Lymphoid

Lymphoma, Neoplasms

NCT02033551 2016-09-27

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Phase 1 Completed

47 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT01017640 2016-07-11

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Phase 1 Completed

20 enrolled

Solid Neoplasm

NCT01154426 2015-07-02

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

31 enrolled

Adult Solid Neoplasm

NCT00535119 2015-05-22

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Phase 1 Completed

107 enrolled

BreastGynecologic

Hereditary Breast and Ovarian Cancer Syndrome

NCT00387608 2012-03-15

ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

Phase 1 Completed

23 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Pre-Operative Radiation and Veliparib for Breast Cancer

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

VelGemRad

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer